The second annual Life & Breath Trail/Fun Run benefiting the Cystic Fibrosis Foundation was held Saturday August 4th in the midst of a steady rain that did not dampen any spirits or prevent 150 runners and walkers from participating.
The Life & Breath Trail/Fun Run was held on the Cherokee Mental Health Institute Campus, with 100 % of the proceeds going to CFF research to help find a cure for Cystic Fibrosis.
According to organizers Carrie and Kevin Lux, as the crew set up in the early morning hours, the grey clouds crept closer and then, just before registration started, the much needed rain began.
"It made for some last minute changes in plans and some soggy paperwork and people, but everything proceeded as scheduled," said Carrie "No one seemed to mind getting soaked this year because we really need rain.
"We were so happy with the turnout in spite of the rainy morning. We had nearly 150 registrants in all this year. Some ran, some walked, some brought young families and strolled, and some simply cheered on the runners in their event T-shirts from under an umbrella. We were really worried when just a few people showed up at first, but then they just kept coming and the support was simply wonderful.
"It all helped make it possible to raise over $7000 for Cystic Fibrosis research. It was overwhelming."
Finishing the 5K at the top of the list were Cara Nelson for the females and Kellen Ludvigson for the males, both from Cherokee. The first place male and female 5K runners each took home a $50 Cherokee cash prize, and several other participants were surprised with some unanticipated cash door prizes and Sioux City Musketeer tickets also, helping to keep the morning full of fun and winners.
"As the event details are wrapped up this week, we are happy to pass along 100% of our proceeds to the Cystic Fibrosis Foundation," explained Carrie.
"This year has been an exciting year in the field as a ground breaking drug was released onto the market in February that actually targets the root cause of CF. While it is only suitable for a small percentage of CF patients, an additional drug is now in sight, recently reaching stage three of FDA approval trials this drug targets around 80% of the CF population.
"The CFF is a main driving force behind this research, and the CF community is almost holding our breath to see what happens.
"We wish to send out a huge thank you to all who supported this event in every way, and plans are already in the works for next year. Thanks to all!"